The Diabesity Battle: Why r-DNA Semaglutide Matters in Routine Care | Dr Kunal Thakkar

How should semaglutide be positioned in the management of type 2 diabetes, obesity and cardiometabolic risk? In this lecture from META MEDICON 2026, Dr Kunal Thakkar, Bhuj, discusses the concept of diabesity and reviews the role of recombinant DNA-based semaglutide in routine clinical practice. The presentation begins with the changing goals of diabetes management—from a purely glucose-centric approach to a broader strategy that also considers weight management, cardiovascular protection, kidney outcomes and long-term complication prevention. Dr Thakkar highlights the importance of early glycaemic control and the concept of metabolic memory, while also emphasizing the clinical impact of weight reduction in patients with type 2 diabetes and obesity. A major focus of the talk is the clinical evidence supporting semaglutide. The lecture reviews the SUSTAIN programme, discussing glycaemic efficacy, HbA1c reduction, weight loss and comparative data with other glucose-lowering therapies. It also addresses cardiovascular outcomes from SUSTAIN 6, kidney-related outcomes from the FLOW trial, and mechanistic insights from the REMODEL trial. Dr Thakkar further discusses once-weekly injectable semaglutide, dose escalation, patient selection and the importance of individualizing therapy according to glycaemic goals, obesity, cardiovascular risk, kidney risk and affordability. The session also includes a discussion on innovator versus alternative semaglutide formulations and the need to balance evidence, quality and patient access in real-world practice. Key topics covered: Diabesity and its growing burden in India Glycaemic legacy and metabolic memory Why early HbA1c control matters Weight reduction in type 2 diabetes Mechanism and clinical role of GLP-1 receptor agonists Semaglutide and the pathophysiology of type 2 diabetes SUSTAIN clinical trial programme HbA1c reduction with semaglutide Weight-loss benefits Cardiovascular risk reduction Kidney outcomes and albuminuria FLOW and REMODEL trials Combining GLP-1 receptor agonists with SGLT2 inhibitors Dose titration and practical clinical use Patient selection and affordability considerations Speaker: Dr Kunal Thakkar, Bhuj Topic: The Diabesity Battle: Why r-DNA Semaglutide is the Right Choice in Routine Care Session: Next-Generation Obesity & Diabetes Pharmacotherapy Conference: META MEDICON 2026 – APICON–CCDSICON Gujarat Chapter 2026 Date: 1 August 2026 Venue: Waves Club, Vadodara Disclosure: As stated by the speaker during the presentation, this was a Novo-sponsored session. This video is intended for medical education and professional academic discussion. Treatment decisions should be individualized according to patient characteristics, approved indications, current evidence and applicable clinical guidelines. #Semaglutide #Diabesity #Type2Diabetes #Obesity #GLP1RA #CardiometabolicHealth #WeightManagement #KidneyProtection #CardiovascularRisk #DiabetesManagement #MedicalEducation #MetaMedicon2026 #IDCM